Introduction {#s1}
============

Neuroendocrine (NE) cells have both neuronal and endocrine phenotypes [@pone.0060905-Montuenga1]. The diffuse neuroendocrine system (DNES) is composed of NE cells scattered throughout the entire body either as single cells or clusters, such as solitary pulmonary NE cells (PNECs) and neuroepithelial bodies (NEBs) [@pone.0060905-Linnoila1], the islets of Langerhans in the pancreas [@pone.0060905-Ahren1], [@pone.0060905-Koh1], gastrointestinal NE cells [@pone.0060905-Dockray1], [@pone.0060905-KuliczkowskaPlaksej1], dermal NE cells (so-called Merkel cells) [@pone.0060905-Tachibana1], adrenal medullary NE cell [@pone.0060905-Mravec1]--[@pone.0060905-Douglas1], and prostate NE cells [@pone.0060905-Abrahamsson1]. PNECs are implicated in regulation of lung maturation and growth, function as oxygen-sensing chemoreceptors and are likely important for lung stem cell niches [@pone.0060905-Linnoila1]. Gastrointestinal NE cells are known to control gastrointestinal secretion, motility, growth, immune cell function and food intake [@pone.0060905-Dockray1]. Though there has been progress in understanding the function of NE cells, the physiological role of NE cells in most other organs is not well understood.

Cells with NE differentiation are also present in many cancer types, with their representation ranging from being the major component in small cell carcinomas of the lung [@pone.0060905-Linnoila1] and prostate [@pone.0060905-Sun1], as well as NE tumors of gastrointestinal tract [@pone.0060905-Gustafsson1], to more limited quantity in other cancers, such as adenocarcinomas of the lung [@pone.0060905-Linnoila1] and prostate [@pone.0060905-Sun1]. Unfortunately, the cell of origin of neoplastic NE cells and their contribution to cancer progression remain insufficiently elucidated [@pone.0060905-Montuenga1], [@pone.0060905-Linnoila1], [@pone.0060905-Sun1], [@pone.0060905-Cheng1].

NE cells are detected by a number of markers, such as chromogranin A (CgA) [@pone.0060905-Gazdar1], neuron-specific enolase (NSE) [@pone.0060905-Schmechel1], neural cell adhesion molecules (NCAMs, so-called CD56) [@pone.0060905-Jin1], calcitonin gene-related peptide (CGRP) [@pone.0060905-Cadieux1] and SYP [@pone.0060905-Wiedenmann1]. However, the use of NSE [@pone.0060905-Haimoto1]--[@pone.0060905-Seshi1] or CD56 [@pone.0060905-Kaufmann1], [@pone.0060905-Lantuejoul1] is limited because of their poor specificity and/or sensitivity. CgA reactivity is strongly dependent on the number of neurosecretory vesicles per cell and is frequently lost in neoplastic NE cells [@pone.0060905-Jensen1], while only subset of NE cells expresses CGRP [@pone.0060905-Weichselbaum1]. In contrast, SYP is expressed in a broad-spectrum of normal and neoplastic NE and neural cells [@pone.0060905-Wiedenmann1], [@pone.0060905-Gould1].

SYP is a major integral membrane protein of small synaptic vesicles and belongs to a family of proteins that includes synaptogyrin (SYG) and synaptoporin [@pone.0060905-Sudhof1]. It has been reported that in cell culture transfection experiments the 1.2 kb upstream region of rat *Syp* promoter is insufficient to confer cell type specific expression [@pone.0060905-Bargou1]. It has also been suggested that NE cell specific silencer elements lay within the 2.6 kb upstream fragment of *Syp* [@pone.0060905-Bargou1]. At the same time, other cell culture studies have reported that neuron-restrictive silencer element *(NRSE),* a binding site for RE-1 silencing transcription factor (REST), a.k.a. neuron-restrictive silencer factor (NRSF), is located within the first intron of *Syp* gene [@pone.0060905-Lietz1]. However, the regulatory region sufficient for accurate *in vivo* expression of SYP remains unknown, thereby preventing development of genetic constructs allowing *Syp*-specific gene expression.

Since SYP is among the most reliable markers for NE cells, we generated mice with *Syp* locus-based Bacterial Artificial Chromosome (BAC) cassettes. We show that in combination with the preserved *NRSE* in the first intron, only the 121 kb upstream and 36 kb downstream regions, but not the 3 kb upstream region, allow for accurate expression of reporter gene in SYP expressing cells in the mouse. We also show that SYP positive cells can be accurately ablated in either the embryo or in the postnatal adult prostate after induction of DTA expression [@pone.0060905-Ivanova1] by Cre-*loxP* mediated recombination in crosses of *SypELDTA* mice with *EIIA-Cre* [@pone.0060905-Lakso1] or *PB-Cre4* [@pone.0060905-Wu1] mice, respectively. The *Syp* containing BAC cassette and generated mice should provide useful tools for studies of NE cell biological roles in development and maintenance of various tissues and organs.

Materials and Methods {#s2}
=====================

Bioinformatics Analyses {#s2a}
-----------------------

Analysis of sequence and species comparisons were performed by using the University of California Santa Cruz Genome Browser (UCSC, <http://genome.ucsc.edu/>).

Generation of *SypELDTA* Mice {#s2b}
-----------------------------

A BAC clone containing approximately 121 kb and 36 kb of 5\' and 3\' DNA flanking the *Syp* locus was modified by insertion of a *loxP-EGFP-Neo cassette-Stop-loxP-DTA-bpA* cassette to replace the sequence spanning intron 1 downstream of *NRSE* to exon 7 of *Syp* locus by homologous recombination. The BAC constructs were microinjected into male pronuclei of fertilized oocytes from FVB/N mice to generate the *SypELDTA* mice. *EIIA-Cre* (FVB/N-Tg(EIIa-cre)C5379Lmgd/J) transgenic mice (The Jackson Laboratory, Bar Harbor, ME, stock number \#003314) [@pone.0060905-Lakso1], *Rosa26Stop^loxP^LacZ* (B6;129S4-*Gt(ROSA)26Sor^tm1Sor^*/J) reporter mice (The Jackson Laboratory, stock number \#003309) [@pone.0060905-Soriano1], and *ARR~2~PB-Cre* transgenic male mice on FVB/N (*PB-Cre4*) [@pone.0060905-Wu1] were described previously. Details about generation of the targeting construct and BAC recombineering are described in the [Materials and Methods S1](#pone.0060905.s013){ref-type="supplementary-material"}.

Ethics Statement {#s2c}
----------------

This study was carried out in strict accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Institutional Laboratory Animal Use and Care Committee at Cornell University (Permit Number: 2000--0116). All efforts were made to minimize animal suffering.

Histotechnology {#s2d}
---------------

Mice euthanized according to schedule were subjected to cardiac perfusion by phosphate-buffered 4% paraformaldehyde. After digital camera photography during necropsy, collected tissues were processed for embedding in paraffin. Histological evaluations were done on 4 µm-thick sections stained with hematoxylin (Mayer\'s haemalum) and eosin. Transverse sections of the whole prostate were scanned by ScanScope (Aperio Technologies, Vista, CA) with 40×objective followed by lossless compression and assessment of all alterations in identical anatomic regions.

Immunohistochemical Analyses {#s2e}
----------------------------

Immunoperoxidase staining of paraffin sections of paraformaldehyde-fixed tissue was performed by a modified avidin-biotin-peroxidase (ABC) technique [@pone.0060905-Nikitin1]. Antigen retrieval was done by boiling the slides in 10 mM citric buffer (pH 6.0) for 10 minutes. The primary antibodies to cytokeratin-8 (CK8), cytokeratin-5 (CK5), SYP and cleaved Caspase-3 were incubated with deparaffinized sections at 4°C overnight. After incubation with methanol (Fisher Scientific, Bohemia, NY, \#A454-4) containing 0.3% hydrogen peroxide (Sigma, St. Louis, MO, \#H1009), sections were subsequently incubated with biotinylated secondary antibody for 30 minutes at room temperature and subsequently detected with the ABC Elite kit (Vector Laboratories, Burlingame, CA, \#PK-6100) and 3,3-diaminobenzidine (DAB; Sigma, \#D4418) as substrate. Hematoxylin was used as the counterstain in immunoperoxidase stainings. Double immunofluorescence staining was performed by incubation of SYP and EGFP, or β-galactosidase primary antibody at 4°C overnight, followed by Alexa-Fluor 594-conjugated and Alexa-Fluor 488- conjugated secondary antibodies. To stain cell nuclei, sections were incubated with a 10 µg/ml solution of 4\',6-diamidino-2-phenylindole (DAPI; Sigma, \#D9542) for 3 min. Antibody sources and dilutions are listed in the [Materials and Methods S1](#pone.0060905.s013){ref-type="supplementary-material"}.

Morphometric quantitative analyses {#s2f}
----------------------------------

Five digital images of serial sections scanned by ScanScope with 40× objective were captured for each slide and transferred to Image J for manual counting of all epithelial cells (at least 1,000 cells) and SYP positive cells among them. The sizes of prostate lobes were determined by measuring the distance from the edge of each lobe to the urethra. The size of each prostatic duct was determined by measuring its diameter.

Western Blot Analyses {#s2g}
---------------------

PCN1, PCN2, and PCN3 cell lysates were prepared using RIPA buffer (Tris-HCl 50 mM, pH 7.4; Nonidet P−40 1%; Na-deoxicholate 0.25%; NaCl 150 mM; EDTA 1 mM; PMSF 1 mM; Aprotinin, leupeptin, pepstatin: 1 µg/mL each; Na~3~VO~4~ 1 mM; NaF 1 mM), separated by 12% SDS-PAGE and transferred to PVDF membrane (Millipore). The membrane was incubated overnight at 4°C with antibodies to detect SYP (Dako, CA, \#A0010, 1∶100), followed by incubation for 1 hour at room temperature with horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology, CA, \#sc-2301, 1∶2000) and developed using chemiluminescent substrate (Thermo scientific, Rockford, IL, \#34077).

Statistical Analyses {#s2h}
--------------------

Statistical analyses were performed with InStat 3.10 and Prism 5.01 software. (GraphPad, Inc., San Diego, CA). Two-tailed unpaired *t*-test was used in all calculations.

Results {#s3}
=======

Genomic Structure of *Syp* Locus and BAC Engineering for the Generation of *SypELDTA* Constructs {#s3a}
------------------------------------------------------------------------------------------------

To identify the region containing all transcriptional *cis*-elements sufficient for accurate SYP expression *in vivo*, we have analyzed the genomic *Syp* locus by using the UCSC Genome Browser. The *Syp* locus is located on mouse chromosome×and contains 7 exons and 6 introns. Locations of *Syp* locus and other surrounding genes are preserved among different species, such as rat and human ([Figure 1A](#pone-0060905-g001){ref-type="fig"}). Notably, *NRSE* within the first intron of *Syp* is highly conserved among closely related mammalian species ([Figure 1B](#pone-0060905-g001){ref-type="fig"}). Furthermore, comparison of the *Syp* upstream region also displays high conservation in proximal (approximate 0 to--600 bp) and distal (approximate−2000 to−3000 bp) regions relative to transcription start site ([Figure 2](#pone-0060905-g002){ref-type="fig"}). It may imply that not only *NRSE* but also the sequences of those conserved regions are involved in conferring the cell type specific expression of SYP. Therefore, for molecular engineering we have decided to use mouse BAC clone *RP23-267C15* because it encompasses the entire *Syp* locus and, thus, is likely to contain all transcriptional *cis*-elements required for recapitulation of the endogenous cell specific gene expression.

![Genomic structure of the *Syp* gene.\
(A) Location of the *Syp* locus on mouse, rat, and human chromosome X. Mouse *Syp* contains 7 exons (black boxes). The translation initiation codon, ATG, is located in the first exon. The *NRSE* is located within the first intron of *Syp*. (B) Sequence comparison of the *NRSE* derived from *Syp* across species.](pone.0060905.g001){#pone-0060905-g001}

![Sequence comparison of upstream region of *Syp* across species.\
Black lines and boxes represent highly conserved areas of the *Syp* upstream region. The position of upstream sequence is relative to the *Syp* transcription start site (0 bp). The assembly dates of the upstream regions are July 2007 (*Mus musculus*), November 2004 (*Rattus norvegicus*), February 2009 (*Homo sapiens*), October 2010 (*Pan troglodytes*), January 2006 (*Macaca mulatta*), July 2007 (*Pongo pygmaeus abelii*), and March 2009 (*Callithrix jacchus*).](pone.0060905.g002){#pone-0060905-g002}

First, *loxP-EGFP-Neo cassette-Stop-loxP-DTA-bpA* sequence was constructed to replace the sequence between 3\' *NRSE* and exon 7 of *Syp* locus in BAC ([Figure S1A](#pone.0060905.s001){ref-type="supplementary-material"}). As a result, the *Syp* promoter specifically drives EGFP expression to label the SYP expressing cells. Following Cre-*loxP* mediated recombination, DTA can be expressed to ablate the SYP expressing cells. Second, the *loxP* site in the backbone of *RP23-267C15* was also replaced with *β-lactamase* sequence to avoid unintended Cre-mediated recombination due to multiple *loxP* sites ([Figure S1B](#pone.0060905.s001){ref-type="supplementary-material"}). The modified BAC construct is named *SypELDTA* (173 kb) ([Figure 3A](#pone-0060905-g003){ref-type="fig"}). It contains 121 kb and 36 kb upstream and downstream DNA sequences flanking the *Syp* gene, respectively. To evaluate applicability of shorter upstream sequence of *Syp* for cell type specific expression, the sequence *SypP*-*loxP-EGFP-Neo cassette-Stop-loxP-DTA-bpA* from *SypELDTA* was retrieved into *pGEM-T* vector. The retrieving BAC construct is named *sSypELDTA* (12 kb; [Figure 3B](#pone-0060905-g003){ref-type="fig"}). It contains a 3 kb upstream fragment of the *Syp* promoter region.

![BAC transgenic constructs.\
(A) *SypELDTA* construct. The purple bar represents the *EGFP* probe. Restriction enzyme sites for Southern blot are indicated. (B) *sSypELDTA* construct. The fragment *SypP-loxP-EGFP-Neo cassette-Stop-loxP-DTA-bpA* from *SypELDTA* was cloned into *pGEM-T* vector. 3 kb upstream fragment of *Syp* was used to drive downstream gene expression.](pone.0060905.g003){#pone-0060905-g003}

BAC Transgene Function in Mammalian and Bacterial Cell Culture {#s3b}
--------------------------------------------------------------

Functionality of BAC construct was tested in cultured prostate cells and bacteria. *sSypELDTA* was transfected into the mouse *p53* and *Rb* deficient prostate adenocarcinoma cell lines PCN1 and PCN3, which were established from prostate carcinomas of *PB-Cre4; p53^loxP/loxP^Rb^loxP/loxP^* mice [@pone.0060905-Zhou1]. Consistent with our observation that PCN3 cells but not PCN1 cells express SYP ([Figure S2A](#pone.0060905.s002){ref-type="supplementary-material"}), EGFP positive cells have been observed only in PCN3 cells ([Figure S2B](#pone.0060905.s002){ref-type="supplementary-material"}-G) after transfection of *sSypELDTA*. Thus, 3 kb upstream fragment of *Syp* promoter region was sufficient to drive the transgene expression specifically in NE cells.

To test for Cre-*loxP* mediated recombination, *sSypELDTA* was electroporated into the *Escherichia coli* (*E. coli*) EL350 system, which contains a tightly controlled arabinose-inducible *Cre* gene. As shown by PCR, successful Cre-*loxP* mediated recombination of *sSypELDTA* in bacterial system was observed after arabinose induction ([Figure S2H](#pone.0060905.s002){ref-type="supplementary-material"}). The construct resulting from Cre-*loxP* mediated recombination was named *SypDTA*. To confirm that DTA expression driven by *Sy*p promoter could be detected after Cre-*loxP* mediated recombination in mouse cells, reverse transcriptase PCR (RT-PCR) was performed with different constructs transfected into PCN1 and PCN3 after Adenovirus-*Cre* (Ad-*Cre*) infection. DTA expression could be detected in *SypDTA*-infected PCN3 cells and *sSypELDTA*-infected PCN3 cells followed by Ad-*Cre* infection. Conversely, no DTA expression could be detected in PCN1 cells. Thus, DTA was expressed specifically in NE cells after Cre-*loxP* mediated recombination ([Figure S2I](#pone.0060905.s002){ref-type="supplementary-material"}).

BAC Transgene Expression in *SypELDTA* Transgenic Mice {#s3c}
------------------------------------------------------

To test transgene expression *in vivo*, *sSypELDTA* and *SypELDTA* DNA were used to generate transgenic lines 141--143 and 144--148, respectively ([Table 1](#pone-0060905-t001){ref-type="table"}). Based on Southern blotting and quantitative PCR (qPCR), all mice of lines 144--148 carried a single copy of transgene, while copy number of *sSypELDTA* transgene was variable among lines 141--143 ([Figure S3](#pone.0060905.s003){ref-type="supplementary-material"}, [Table 1](#pone-0060905-t001){ref-type="table"}).

10.1371/journal.pone.0060905.t001

###### Characterization of transgenic lines 141--148.

![](pone.0060905.t001){#pone-0060905-t001-1}

  Transgene      Line   Male germ line transmission               Copy number               Transgene expression in prostate NE cells (%)[\*](#nt101){ref-type="table-fn"}   Transgene expression in prostate non-NE cells
  ------------- ------ ----------------------------- ------------------------------------- -------------------------------------------------------------------------------- -----------------------------------------------
  *sSypELDTA*    141                Yes                               11                                                          72                                                              Yes
                 142                Yes                                2                                                          81                                                              Yes
                 143                Yes               ND[\#](#nt102){ref-type="table-fn"}                                         ND                                                              Yes
  *SypELDTA*     144                No                                 1                                                          ND                                                              ND
                 145                Yes                                1                                                          88                                                              No
                 146                No                                ND                                                          ND                                                              ND
                 147                Yes                                1                                                          90                                                              No
                 148                Yes                                1                                                          83                                                              No

Percentage of EGFP; SYP double positive cells within total number of SYP positive cells was determined by double immunofluorescence staining.

Not done.

To confirm the specificity of transgene expression in transgenic mice, co-localization of transgene-derived EGFP and endogenous SYP has been determined by double immunofluorescence staining in prostate NE cells ([Figure 4A](#pone-0060905-g004){ref-type="fig"}). *sSypELDTA* transgenic mice had expression of transgene in non-NE epithelium cells of the prostate ([Figure S4](#pone.0060905.s004){ref-type="supplementary-material"}, [Table 1](#pone-0060905-t001){ref-type="table"}). In contrast, no EGFP expression was detected in SYP negative cells ([Figure S5](#pone.0060905.s005){ref-type="supplementary-material"}, [Table 2](#pone-0060905-t002){ref-type="table"}) of *SypELDTA* mice. Among 5 tested transgenic lines, the line 147 had the highest frequency (90%) of SYP positive NE cells co-expressing EGFP ([Table 1](#pone-0060905-t001){ref-type="table"}). Furthermore, co-expression of EGFP and SYP in line 147 has also been observed in the lung NE cells ([Figure 4B](#pone-0060905-g004){ref-type="fig"}), medulla of adrenal gland ([Figure 4C](#pone-0060905-g004){ref-type="fig"}), islets of Langerhans in pancreas ([Figure 4D](#pone-0060905-g004){ref-type="fig"}), and brain ([Figure 4E](#pone-0060905-g004){ref-type="fig"}).

![*SypELDTA* transgene expression is highly specific for SYP expressing cells.\
(A-E) Co-expression of EGFP (green) and SYP (red) in prostate NE cells (A), lung NE cells (B; inset: high magnification), medulla of adrenal gland (C), pancreatic islets of Langerhans (D), and brain (E) of *SypELDTA* transgenic mice. Yellow color (arrows) indicates co-localization of EGFP and SYP fluorescent signals. Counterstaining with DAPI, blue. Calibration bar: 18 µm (A), 37 µm (B), 50 µm (C-E), 8 µm (inset).](pone.0060905.g004){#pone-0060905-g004}

10.1371/journal.pone.0060905.t002

###### Transgene expression in *SypELDTA* line 147.

![](pone.0060905.t002){#pone-0060905-t002-2}

  Tissue                      Transgene expression in SYP expressing cells (%)[\*](#nt103){ref-type="table-fn"}   Transgene expression in non-SYP expressing cells
  -------------------------- ----------------------------------------------------------------------------------- --------------------------------------------------
  Brain                                                              100                                                                 0
  Lung                                                               92                                                                  0
  Medulla of adrenal gland                                           98                                                                  0
  Islets of Langerhans                                               100                                                                 0

Percentage of EGFP; SYP double positive cells within total number of SYP positive cells was determined by double immunofluorescence staining.

DTA Expression in *EIIA-Cre; SypELDTA* Embryo {#s3d}
---------------------------------------------

To confirm that DTA expression driven by *Syp* promoter is able to ablate SYP positive cell lineage, DTA expression was examined by crossing the male *SypELDTA* mice of line 147 with female *EIIA-Cre* transgenic mice, following collection of embryos on gestational day (GD) 10.5 ([Figure 5A](#pone-0060905-g005){ref-type="fig"}). Adenoviral *EIIA* promoter targets expression of Cre recombinase to the early mouse embryo and Cre-mediated recombination occurs in a wide range of tissues, thereby allowing assessing effects of transgene expression in multiple organs and tissues [@pone.0060905-Lakso1]. *EIIA-Cre; SypELDTA* embryos had rare SYP positive cells in the brain and dorsal root ganglia ([Figure 5B, D, F](#pone-0060905-g005){ref-type="fig"}). Consistent with induction of apoptosis pathway by DTA [@pone.0060905-Chang1], [@pone.0060905-Chang2], a significant number of cleaved Caspase-3 positive cells were detected in the same structures ([Figure 5C, E, G](#pone-0060905-g005){ref-type="fig"}). The brain and dorsal root ganglia of *EIIA-Cre* littermates had abundant SYP positive cells ([Figure 5H, J, L](#pone-0060905-g005){ref-type="fig"}), but almost no cleaved Caspase-3 positive cells ([Figure 5I, K, M](#pone-0060905-g005){ref-type="fig"}). Thus, our construct was effective in conditional ablation of SYP expressing cells by DTA *in vivo*.

![*EIIA-Cre; SypELDTA* embyros exhibit massive cell death in SYP positive cells.\
(A) Design of crosses between male *SypELDTA* and female *EIIA-Cre* transgenic mice. (B-M) SYP (B, D, F, H, J, L) and cleaved Caspase-3 (C, E, G, I, K, M) expression (arrows) in serial sections of *EIIA-Cre; SypELDTA* (B-G) and *EIIA-Cre* (H-M) embryos collected on gestational day 10.5. High (D-G, J-M) magnification images of brain (D, E, J, K) and dorsal root ganglion (F, G,L, M) regions shown as rectangles in low magnification images (B, C, H, I). b, brain, g, dorsal root ganglia. ABC Elite method. Hematoxylin counterstaining. Calibration bar: 950 µm (B, C, H, I), 50 µm (D-G, J-M).](pone.0060905.g005){#pone-0060905-g005}

Effect of Prostate Epithelium-Specific NE Cell Ablation {#s3e}
-------------------------------------------------------

Modified *probasin* promoter drives expression of Cre recombinase in the prostate epithelium of postnatal mouse prostate of *PB-Cre4* transgenic mice [@pone.0060905-Wu1], [@pone.0060905-Chen1]. By using *PB-Cre4* mice we have previously determined that deletion of tumor suppressor genes *p53* and *Rb* results in prostate carcinomas with NE differentiation [@pone.0060905-Zhou1], [@pone.0060905-Zhou2]. We have also reported that expansion of NE cells is observed in prostate adenocarcinomas in *PB-Cre4; Pten^loxP/loxP^* mice, particularly after castration [@pone.0060905-Liao1]. To verify that Cre recombinase under the control of *probasin* promoter is expressed in NE cells, which are concentrated in the prostate proximal region ([Figure S6](#pone.0060905.s006){ref-type="supplementary-material"}), Cre-mediated recombination in prostate NE cells was examined by crossing *PB-Cre4* transgenic mice [@pone.0060905-Wu1] with R26R reporter mice [@pone.0060905-Soriano1]. The expression of β-galactosidase is possible only after Cre-mediated deletion of a stop codon flanked by *loxP* sites. Double immunofluorescence staining showed co-localized expression of β-galactosidase and SYP in the proximal region of prostatic ducts of *PB-Cre4; R26R* mice. Thus, Cre-*loxP* mediated recombination occurs in NE cell lineage after Cre expression directed by *probasin* promoter ([Figure S7](#pone.0060905.s007){ref-type="supplementary-material"}).

To evaluate whether prostate epithelium-specific NE cell ablation impacts prostate development and function, male *PB-Cre4* transgenic mice have been crossed with female *SypELDTA* (lines 147 and 148) mice to get *PB-Cre4; SypELDTA* male offspring ([Figure 6A](#pone-0060905-g006){ref-type="fig"}). Both lines shown similar phenotypes and line 147 has been characterized to the fullest extent. As compared to wild-type (FVB/N) and *SypELDTA* (147) age-matched controls and littermates, the size of prostate of *PB-Cre4; SypELDTA* (AP147) was smaller ([Figure 6B](#pone-0060905-g006){ref-type="fig"}, S8). In agreement with earlier reports of broad *PB-Cre4* transgene expression in the prostate epithelium [@pone.0060905-Wu1], loss of floxed *EGFP* was reproducibly observed in all prostate lobes according to microdissection-PCR genotyping of AP147 ([Figure S9](#pone.0060905.s009){ref-type="supplementary-material"}). However, only the NE cell population was diminished by 60% in AP147 mice as compared to controls according to immunostaining for SYP in the proximal regions of prostatic ducts (147 vs. AP147: 1.19±0.34% vs. 0.5±0.19%, P\<0.0001; [Figure 6C-E](#pone-0060905-g006){ref-type="fig"}). The decrease was observed consistently in various areas of the proximal region, such as ventral (1.07±0.22% vs. 0.55±0.18%, P\<0.0001; [Figure 6F](#pone-0060905-g006){ref-type="fig"}) and dorsolateral (1.42±0.39% vs. 0.44±0.19%, P\<0.0001; [Figure 6G](#pone-0060905-g006){ref-type="fig"}) lobes. In addition, the average diameter of prostatic ducts in distal regions was decreased, especially in the dorsolateral lobe ([Figure S10](#pone.0060905.s010){ref-type="supplementary-material"}). Interestingly, more NE cells were observed (1.42±0.39% vs. 1.07±0.22%, P = 0.0252; [Figure 6H](#pone-0060905-g006){ref-type="fig"}) and higher percentage of NE cells was ablated (70% vs. 49%; [Figure 6F, G](#pone-0060905-g006){ref-type="fig"}) in the proximal regions of prostatic ducts of dorsolateral lobes, as compared to those of ventral lobes, which could be associated with the smaller diameter of prostatic ducts in dorsolateral lobes.

![*PB-Cre4; SypELDTA* line 147 mice show decreased number of NE cells and prostate hypotrophy.\
(A) Design of crosses between male *PB-Cre4* and female *SypELDTA* transgenic mice resulting in male *PB-Cre4; SypELDTA* offspring with prostate epithelium-specific NE cell ablation. (B) Gross images of the prostate from wild-type FVB/N (FVB), *SypELDTA* (147), *PB-Cre4; SypELDTA* (AP147) mice. Calibration bar: 0.5 cm. (C, D) Detection of SYP positive NE cells (arrows) in the prostate proximal region of age-matched *SypELDTA* (C; n = 4) and *PB-Cre4; SypELDTA* (D; n = 4) mice. ABC Elite method. Hematoxylin counterstaining. Calibration bar: 50 µm. (E-G) Quantification of NE cells in the proximal regions of whole prostate (E), and in the proximal regions of ventral (F) and dorsolateral (G) lobes of prostates from age-matched *SypELDTA* (147; n = 4) and *PB-Cre4; SypELDTA* (AP147; n = 4) mice. (H) Quantification of NE cells in proximal regions of dorsolateral and ventral lobes of the prostates from *SypELDTA* mice (n = 4). \*P\<0.05. \*\*\*P\<0.001. All error bars denote SD.](pone.0060905.g006){#pone-0060905-g006}

Except for the size of lumens, there were no significant changes in overall morphology of prostatic ducts in the ventral and dorsolateral lobes of AP147 mice, or in either the proximal or distal regions of prostatic ducts ([Figure S10](#pone.0060905.s010){ref-type="supplementary-material"}). NE cell ablation did not result in any detectable changes to the extent of luminal (CK8) and basal (CK5) differentiation in the proximal and distal regions of ducts ([Figure S11](#pone.0060905.s011){ref-type="supplementary-material"}). No significant cell death was observed in luminal and basal cells in any of the regions ([Figure S12](#pone.0060905.s012){ref-type="supplementary-material"}), which implies a tight regulation of *Syp* promoter in prostate non-NE epithelium cells. Taken together, these results support the notion that NE cells play an important role in prostate development.

Discussion {#s4}
==========

Previous report indicated that 2.6 kb but not 1.2 kb upstream fragment of *Syp* was sufficient to confer cell type specific expression [@pone.0060905-Bargou1]. Consistent with this observation, we have found high evolutionary conservation not only in the proximal (0 to --600 bp) but also distal (−2000 to −3000 bp) regions of the *Syp* gene. Based on this information, we have designed transgenic constructs preserving *NRSE* in the first intron of *Syp* gene and containing either 3 kb or 121 kb upstream regulatory sequence. While 3 kb sequence was sufficient for NE specific expression of transgene in cultured cells, it did not assure specificity of gene expression in the transgenic mice. At the same time, a longer promoter has been highly specific for NE cells. These results suggest that other *cis*-elements, farther than 3 kb upstream fragment, provide the cell type specific expression in the context of the whole organism. It is also possible that the 36 kb 3\' flanking region of *Syp* might play a role in regulating cell specificity as well, similarly to other genes, such as human *tyrosine hydroxylase* [@pone.0060905-Wong1]. Also, longer upstream and downstream regions of *Syp* locus may better insulate the *Syp* promoter from position effects by other genes at the site of transgene integration [@pone.0060905-Yang1]. However, given NE cell specific expression of 3 kb construct after its multi-copy integration in cell culture, the latter possibility is less likely. Identification of environment driven mechanisms responsible for accurate gene expression should allow much better understanding of *Syp* regulation.

It should be noted that in addition to NE cells, SYP is also expressed in neurons of the nervous system [@pone.0060905-Wiedenmann1], [@pone.0060905-Gould1]. Unlike other REST regulated genes, such as *BDNF* and *GluR2* genes, *Syp* is similarly regulated in neuronal and NE cells [@pone.0060905-Hohl1]. Consistently, we have observed broad expression of *Syp* driven EGFP and DTA in mouse neurons of the brain and spinal ganglia. Thus, our model can be used for targeted ablation of NE and/or neuronal cells depending on a particular *Cre* driving promoter.

Some neuropeptides, such as calcitonin gene-related peptide (CGRP) and gastrin-releasing peptide (GRP) are expressed only in subsets of NE cells [@pone.0060905-Weichselbaum1], [@pone.0060905-diSantAgnese1], [@pone.0060905-Sunday1]. Therefore, theoretically it is possible that some NE cells do not express SYP. Although we were unable to find any literature supporting this possibility, our *SypELDTA* mice should allow detection of such cells by using double immunofluorescence for various NE markers before and after *Syp*-driven ablation in future.

As a proof of the utility of our model, we performed prostate epithelium-specific ablation of NE cells. The mouse prostate is composed of a series of branching ducts, each containing distal, intermediate and proximal regions relative to the urethra [@pone.0060905-Sugimura1]. Each duct contains three differentiated cell types: luminal, basal and NE cells, with stem cells preferentially concentrated in the proximal region [@pone.0060905-Salm1]--[@pone.0060905-Leong1]. NE cells secrete a large number of neuropeptides which can be mitogenic and growth-promoting. Receptors for some of the NE products have been found to be expressed in benign prostate and/or prostate cancer. It has been proposed that the NE cells may regulate the growth, differentiation and secretory activity of the prostatic epithelium, possibly through a paracrine mechanism [@pone.0060905-Abrahamsson1]. However, studies directly addressing role of NE cells in prostate development have been lacking.

Based on co-detection of SYP and EGFP double immunofluorescence, as well as lack of Cre-mediated recombination and cell death in prostate non-NE epithelium cells of *PB-Cre4; SypELDTA* mice, expression of *SypELDTA* has been highly specific to SYP positive prostate NE cells. Consistent with the important role of NE cells in prostate biology, prostates with decreased number of NE cells were hypotrophic, with decreased sizes of prostate lobes and reduced average diameters of prostatic ducts. Notably, the most pronounced effect of NE ablation on prostate hypotrophy was in the dorsolateral prostate, where NE cells were ablated to the greatest extent. Our study also indicates that NE cells are located in the proximal regions of the prostatic ducts, the area of preferential stem cell location. Future in-depths studies should address the kinetics of NE cell ablation effects and explore if the effect of NE cells on prostate size can be explained by their proximity to prostate stem cells.

It should be noted that in spite of 90% gene expression specificity in prostate NE cells of *SypELDTA* line 147 mice, we observed only 60% decrease in number of prostate NE cells in *PB-Cre4; SypELDTA* mice. Consistent with previous study describing compartmentalization of gene expression between prostate lobes [@pone.0060905-Abbott1], our results support a possibility that efficiency of Cre-mediated homologous recombination is different in NE cells of a particular region. We also cannot exclude that there are intrinsic differences in regulation of gene expression in individual NE cells, which may lead to the reduction of DTA expression in some of them. Thus, further improvements in design of constructs for highly efficient NE cell ablation may yield even more dramatic effect on prostate hypotrophy.

NE cell differentiation is positively correlated with prostate cancer progression, castrate-resistance and poor prognosis [@pone.0060905-Sun1], [@pone.0060905-Debes1]. Previous reports have indicated that NE cells can stimulate cell proliferation, invasion, and apoptosis resistance of cultured prostate cancer cells [@pone.0060905-Sun1]. However, specific mechanisms involved in the pathogenesis of NE differentiation are not well known. Crossing *PB-Cre4; SypELDTA* transgenic mice with *Pten* knockout mice [@pone.0060905-Liao1], [@pone.0060905-Wang2] or other established mouse prostate cancer models with preferential NE differentiation, such as TRAMP or LADY [@pone.0060905-KaplanLefko1], [@pone.0060905-Masumori1], should decisively determine the role of NE cells in prostate carcinogenesis. More generally, *SypELDTA* mice should be useful for studying other NE neoplasms, such as small cell lung carcinoma and NE tumors in the gastrointestinal tract [@pone.0060905-Montuenga1], [@pone.0060905-Linnoila1], [@pone.0060905-Sun1].

Taken together, we have identified a region of *Syp* gene sufficient for faithful expression of genetic constructs. We have also successfully generated the *SypELDTA* mouse model suitable for flexible organ-specific detection and ablation of NE cells. This model system should provide an important tool for studies of NE cell functions in development and carcinogenesis in various tissues.

Supporting Information {#s5}
======================

###### 

**Generation of the BAC targeting construct.** (A) The targeting strategy was to replace exon region of the *Syp* locus with *loxP-EGFP-Neo cassette-Stop-loxP-DTA-bpA* by homologous recombination. Exon 1 and intron 1 have been preserved because of the *NRSE* sequence, which is essential for silencing activity in non-neuronal cells. Start codon ATG in exon 1 was mutated to alanine codon GCA. *SypP*: *synaptophysin* promoter. *NRSE*: neuro-restrictive suppressor element. (B) The backbone of *RP23-267C15* (*pBACe3.6* vector) contains a *loxP* site which has been replaced with *β-lactamase* sequence by homologous recombination. The modified BAC construct was named *SypELDTA.*

(TIF)

###### 

Click here for additional data file.

###### 

**Functional testing of** ***sSypELDTA*** **in cultured prostate NE cells and** ***E. coli*** **.** (A) SYP expression in PCN1-PCN3 cells by western blotting. GAPDH, internal control. (B-G) Detection of EGFP expression by BAC transgene in prostate cancer cell line with NE differentiation (PCN3, C, E, G, arrows), but not in line without NE differentiation (PCN1, B, D, F). (B, C) Light microscopy, (D, E) green fluorescence, (F, G) merged images. Calibration bar: 200 µm (B-G). (H) Detection of Cre-*loxP* mediated recombination in *sSypELDTA* transgenic construct in the bacterial system EL350. EL350 bacteria, which contain endogenous arabinose-inducible *Cre*, were transformed with *sSypELDTA* transgenic construct and induced with arabinose. PCR genotyping was performed with F1/F2/R1 primers without (lane 2) and with (lane 3) arabinose induction. 256 bp and 617 bp fragments are diagnostic for internal control (primer F2/R1) and Cre-mediated recombination (primer F1/R1), respectively. Lane 1: marker (M). (I) Detection of DTA expression by *sSypELDTA* transgenic construct in the prostate cancer cell lines by RT-PCR. Lane 1: marker (M); Lane 2 (without RT) and Lane 3 (with RT): no transfection; Lane 4 (without RT) and Lane 5 (with RT): *PGKDTAbpA* transfection; Lane 6 (without RT) and Lane 7 (with RT): *sSypELDTA* transfection; Lane 8 (without RT) and Lane 9 (with RT): *sSypELDTA* transfection followed by Ad-*Cre* infection; Lane 10 (without RT) and Lane 11 (with RT): *SypDTA* transfection. 657 bp fragment is diagnostic for DTA mRNA; RT, reverse transcriptase.

(TIF)

###### 

Click here for additional data file.

###### 

**The transgene copy number in mice of** ***sSypELDTA*** **lines 141-143 and** ***SypELDTA*** **lines 144-148.** (A) Experimental design. (B) Southern blot analysis of transgenic line 141. Genomic DNA digested with restriction enzymes AscI (Lane 2), PacI (Lane 3), and AscI, PacI and AflII (Lane 4). Lane 1: DNA marker (M). AflII but not AscI and PacI restriction sites are present within the transgene. 8,466 bp band in lane 4 is diagnostic for multiple transgene copies integrated into a single genomic site, whereas top band (arrow) is diagnostic for single copy of transgene. *EGFP*, DNA probe. (C) Quantification of transgene copy number in transgenic lines by quantitative PCR. Transgenic line 141 carrying 11 copies of transgene was used as a reference to estimate copy number of other lines. (D) Genotyping analysis of transgenic line 147. The upper bands are diagnostic for *EGFP* (lane 2, E, 346 bp), *Neomycin* (lane 3, N, 342 bp), and *DTA* (lane 4, D, 348 bp) fragments of transgene. 196 bp band in lanes 2-4 is internal control (endogenous *Rb*). Lane 1: DNA marker (M).

(TIF)

###### 

Click here for additional data file.

###### 

**Transgene expression in** ***sSypELDTA*** **lines 141-143.** (A-H) Detection of EGFP (B, D, F, H, green) and SYP (C, D, G, H, red) expression (arrows) in non-NE (A-D) and NE cells (E-H) of the prostate epithelium. Yellow color in overlay (D, H) indicates co-localization of EGFP and SYP fluorescent signals. Counterstaining with DAPI (A, D, E, H, blue). Calibration bar: 50 µm (A-D), 18 µm (E-H).

(TIF)

###### 

Click here for additional data file.

###### 

***SypELDTA*** **transgene expression has high specificity in SYP expressing cells.** (A-T) Detection of EGFP (B, D, F, H, J, L, N, P, R, T, green) and SYP (C, D, G, H, K, L, O, P, S, T, red) expression (arrows) in prostate NE cells (A-D), lung NE cells (E-H), medulla of adrenal gland (I-L), islets of Langerhans in pancreas (M-P), and brain (Q-T) of *SypELDTA* line 147 transgenic mice. Yellow color in overlay (D, H, L, P, T) indicates co-localization of EGFP and SYP fluorescent signals. Counterstaining with DAPI (A, D, E, H, I, L, M, P, Q, T, blue). Calibration bar: 25 µm (A-D), 50 µm (E-T).

(TIF)

###### 

Click here for additional data file.

###### 

**NE cells are mostly located in the proximal region of prostatic ducts.** (A, B) SYP expression in NE cells in proximal (A) and distal (B) regions of prostatic ducts of the prostate (n = 6). NE cells and nerve terminals are indicated by arrows and arrowheads, respectively. Calibration bar: 50 µm (A), 100 µm (B). (C) Quantification of SYP positive NE cells. Distal regions of prostatic ducts contain no NE cells. Error bar denotes SD.

(TIF)

###### 

Click here for additional data file.

###### 

**Cre recombinase under the control of** ***probasin*** **promoter is expressed in prostate NE cells.** (A-D) Detection of SYP (B, D, green) and β-galactosidase (C, D, red, indicative of Cre-*loxP* mediated recombination) expression (arrows) in the prostate NE cells in *PB-Cre4; R26R* mice harboring *Probasin*-*Cre* and *lacZ* reporter gene. Yellow color in overlay (D) indicates co-localization of SYP and β-galactosidase fluorescent signals. Counterstaining with DAPI (A, D, blue). Calibration bar: 50 µm (A-D).

(TIF)

###### 

Click here for additional data file.

###### 

**Reduced size of prostate lobes in** ***PB-Cre4; SypELDTA*** **mice.** (A-D) Quantification of size of anterior (A), dorsal(B), lateral (C), and ventral (D) lobes among age-matched FVB/N (FVB, n = 4), *SypELDTA* (147; n = 4), and *PB-Cre4; SypELDTA* (AP147; n = 4) mice. \*P\<0.05. \*\*P\<0.01. Error bar denotes SD.

(TIF)

###### 

Click here for additional data file.

###### 

***PB-Cre*** **drives Cre-** ***loxP*** **recombination in the prostate of** ***PB-Cre4; SypELDTA*** **mice.** (A-F) Microdissection-PCR. Proximal (A) and distal (ventral, B, dorsolateral, C, and anterior, D) regions of prostatic ducts and the muscular layer of the prostate (E) of age-matched *SypELDTA* (147) and *PB-Cre4; SypELDTA* (AP147) mice before and after microdissection. Hematoxylin and eosin. Calibration bar: 50 µm (A-E). (F) PCR design and detection of Cre-*loxP* mediated recombination in microdissected proximal region (P, lane 2 and 7), and ventral (V, lane 3 and 8), dorsolateral (DL, lane 4 and 9), anterior (A, lane 5 and 10) distal regions, and muscular layer (ML, lane 6) of prostates from *SypELDTA*(lanes 2-5) and *PB-Cre4; SypELDTA* (lanes 6-10) mice. 346 bp fragment is generated with primers F1and R1and is diagnostic for *EGFP* (present before Cre-loxP mediated recombination). 196 bp fragment (endogenous *Rb*) is internal control. Lane 1: marker (M).

(TIF)

###### 

Click here for additional data file.

###### 

**NE cell ablation results in proportional reduction of prostatic duct diameters in distal regions.** (A-I) Histology (A, B, D, E, G, H) and quantification of diameters (C, F, I) of proximal (A, B, C) and distal (ventral, D, E, F, and dorsolateral, G, H, I) regions of prostatic ducts of age-matched *SypELDTA* (147; n = 6; A, D, G) and *PB-Cre4; SypELDTA* (AP147, n = 6; B, E, H) mice. Hematoxylin and eosin. Calibration bar: 50 µm (A, B), 100 µm (D, E, G, H). \*P\<0.05. \*\*P\<0.01. All error bars denote SD.

(TIF)

###### 

Click here for additional data file.

###### 

**NE cell ablation does not affect luminal (CK8+) or basal (CK5+) cell differentiation.** (A-L) Detection of CK8 (A-F) and CK5 (G-L) expression (brown) in epithelial cells of proximal (A, D, G, J) and distal (ventral, B, E, H, K, and dorsolateral, C, F, I, L) regions of prostatic ducts in age-matched *SypELDTA* (147, A-C, G-I) and *PB-Cre4; SypELDTA* (AP147, D-F, J-L) mice. ABC Elite method. Hematoxylin counterstaining. Calibration bar: 50 µm (A-L).

(TIF)

###### 

Click here for additional data file.

###### 

**No significant cell death is observed in prostate epithelium non-NE cells in** ***PB-Cre4; SypELDTA*** **mice.** (A-F) cleaved Caspase-3 expression in proximal (A, B), and distal (ventral, C, D, and dorsolateral, E, F) regions of prostatic ducts in age-matched *SypELDTA* (147, A, C, E) and *PB-Cre4; SypELDTA* (AP147, B, D, F) mice. The staining of embryonic dorsal root ganglia ([Figure 5](#pone-0060905-g005){ref-type="fig"}) served as a positive control for cleaved Caspase-3 immunostaining. ABC Elite method. Hematoxylin counterstaining. Calibration bar: 50 µm (A-F).

(TIF)

###### 

Click here for additional data file.

###### 

**Detailed protocol descriptions for generation of the targeting construct and BAC recombineering, genotyping, cell culture experiments, transgene copy number quantification, antibody sources and dilutions of immunohistochemical analyses, and microdissection-polymerase chain reaction.**

(DOCX)

###### 

Click here for additional data file.
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